Cutler Group’s Organogenesis Holdings ORGO Stock Holding History

Cutler Group’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,500	Closed	-$26K	–	5468
2022 Q1	$26K	Buy	+3,500	New	+$27.1K	﹤0.01%	2826

Other funds holding ORGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's ORGO Position: Q2 2022 in Review

Cutler Group sold out of Organogenesis Holdings (ORGO) in Q2 2022, closing a stake of 3,500 shares — an estimated $26K sold.

Cutler Group first reported a position in ORGO in Q1 2022 and held it in 1 quarter. The position peaked at $26K in Q1 2022. 146 funds tracked by Wall St. Rank hold ORGO as of Q2 2022.

Cutler Group reported no remaining Organogenesis Holdings position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 3,500 Organogenesis Holdings shares in Q2 2022, an estimated $26K.
Cutler Group first reported a position in Organogenesis Holdings in Q1 2022 and held it in 1 quarter.
Cutler Group's Organogenesis Holdings position peaked at $26K in Q1 2022.
146 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.